Biodegradable microencapsulation for controlled release of hydrophobic liquids
A novel biodegradable microencapsulation technology allows controlled release of hydrophobic liquids. Tunable polymers enable precise encapsulation and release rates, with applications in pharmaceuticals, agriculture, and personal care products.
Overview
This innovative solution leverages biodegradable microencapsulation to provide controlled release of hydrophobic liquids. Utilizing a proprietary family of low-melt liquid polymers, these microcapsules are designed to encapsulate a wide range of hydrophobic active ingredients. The unique capability of this technology lies in its ability to adjust the encapsulation efficiency and release rates by modifying the chemical structure of the polymers and the physical properties of the microcapsule shell. This presents significant opportunities in industries such as pharmaceuticals, agriculture, and personal care, where precise delivery and environmental safety are paramount.
Technical specifications
- Biodegradable polymers: Synthesized to be miscible with hydrophobic liquids, allowing for efficient encapsulation.
- Controlled release: Release rates of active ingredients can be tailored through shell thickness and density.
- Environmentally safe: Microcapsules degrade via hydrolysis into non-toxic compounds.
- Versatile applications: Adaptable to various hydrophobic cargos with potential utility in multiple industries.
- Production process: Conducted under mild conditions, which includes room temperature synthesis, with optional use of organic solvents.
Technology readiness level
Currently at TRL 3, this technology has been validated in controlled lab settings, including cell and animal studies demonstrating safety and efficacy. Future validation will focus on optimizing polymer formulations, scaling up production, and ensuring product stability and shelf-life under storage conditions.
About University of Minnesota
The University of Minnesota is a flagship, comprehensive public research university spanning multiple campuses, with a large research enterprise and clinical integration. Industry engages through co-located labs on the Twin Cities campuses, access to an academic health system for clinical translation, and pilot and field-testing facilities that speed scale-up. A statewide extension network and outreach centers provide real-world sites and data partnerships across Minnesota, while proximity to a dense medtech and Fortune 500 corridor enables frequent collaboration. Research is supported by competitive federal funding, including NIH, NSF, DOE, USDA, and DoD. A dedicated technology transfer office manages IP, licensing, sponsored research agreements, and startup incubation to speed commercialization.
delivered to your inbox.